Sanofi マネジメント

マネジメント基準チェック /34

Sanofi'sの CEO はPaul Hudsonで、 Sep2019年に任命され、の在任期間は 4.75年です。の年間総報酬は€ 10.57Mで、 13.2%給与と86.8%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.006%を直接所有しており、その価値は€ 6.26M 。経営陣と取締役会の平均在任期間はそれぞれ4.3年と4.2年です。

主要情報

Paul Hudson

最高経営責任者

€10.6m

報酬総額

CEO給与比率	13.2%
CEO在任期間	5.1yrs
CEOの所有権	0.006%
経営陣の平均在職期間	4.2yrs
取締役会の平均在任期間	4.5yrs

経営陣の近況

Recent updates

CEO報酬分析

Sanofi の収益と比較して、Paul Hudson の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	€5b
Jun 30 2024	n/a	n/a	€4b
Mar 31 2024	n/a	n/a	€5b
Dec 31 2023	€11m	€1m	€5b
Sep 30 2023	n/a	n/a	€9b
Jun 30 2023	n/a	n/a	€9b
Mar 31 2023	n/a	n/a	€8b
Dec 31 2022	€11m	€1m	€8b
Sep 30 2022	n/a	n/a	€6b
Jun 30 2022	n/a	n/a	€7b
Mar 31 2022	n/a	n/a	€7b
Dec 31 2021	€11m	€1m	€6b
Sep 30 2021	n/a	n/a	€6b
Jun 30 2021	n/a	n/a	€6b
Mar 31 2021	n/a	n/a	€12b
Dec 31 2020	€11m	€1m	€12b
Sep 30 2020	n/a	n/a	€11b
Jun 30 2020	n/a	n/a	€11b
Mar 31 2020	n/a	n/a	€3b
Dec 31 2019	€6m	€433k	€3b

報酬と市場: Paulの総報酬 ($USD 11.35M ) は、 UK市場 ($USD 5.78M ) の同規模の企業の平均を上回っています。

報酬と収益: Paulの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Paul Hudson (57 yo)

5.1yrs

在職期間

€10,571,822

報酬

Mr. Paul Hudson serves as Chief Executive Officer of Sanofi at Hoechst Pakistan Limited (formerly known as sanofi-aventis Pakistan Limited). He has been Chief Executive Officer at Sanofi since September 1,...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Paul Hudson	CEO & Director	5.1yrs	€10.57m	0.0056% € 7.1m
François-Xavier Roger	Executive VP & CFO	less than a year	データなし	データなし
Madeleine Roach	Executive VP & Head of Business Operations	less than a year	データなし	データなし
Laurent Gilhodes	Principal Accounting Officer and Vice President of Corporate Accounting	no data	データなし	データなし
Josephine Fubara	Chief Science Officer of Consumer Health Care	no data	データなし	データなし
Thomas Larsen	Head of Investor Relations	less than a year	データなし	データなし
Dante Beccaria	Global Compliance Officer & VP	12.5yrs	データなし	データなし
Roy Papatheodorou	Executive VP & General Counsel	2.7yrs	データなし	データなし
Josep Catlla	Head of Communications	no data	データなし	データなし
Pierre Chancel	Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing	20.2yrs	データなし	データなし
Natalie Bickford	Executive VP & Chief People Officer	4.2yrs	データなし	データなし
Marie-Hélène Laimay	Senior Vice President of Audit & Internal Control Assessment	22.4yrs	データなし	データなし

4.2yrs

平均在職期間

55.5yo

平均年齢

経験豊富な経営陣: 0O59の経営陣は経験豊富であると考えられます ( 4.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Paul Hudson	CEO & Director	5yrs	€10.57m	0.0056% € 7.1m
Jean-François Dehecq	Honorary Chairman	14.4yrs	€4.71m	データなし
Serge Weinberg	Honorary Chairman	1.4yrs	€324.96k	0.00013% € 163.1k
Patrick Kron	Independent Director	10.4yrs	€175.75k	0.000080% € 100.4k
Lise Kingo	Independent Director	4.5yrs	€148.25k	0.000080% € 100.4k
Frederic Oudea	Independent Chairman	1.4yrs	€573.52k	0.000080% € 100.4k
Fabienne Lecorvaisier	Independent Director	11.4yrs	€156.50k	0.000080% € 100.4k
Gilles Schnepp	Independent Director	2.8yrs	€175.75k	0.000080% € 100.4k
Rachel Duan	Independent Director	4.5yrs	€145.50k	0.000080% € 100.4k
Barbara Lavernos	Director	3.5yrs	€134.50k	0.000080% € 100.4k
Christophe Babule	Director	5.7yrs	€134.50k	0.000080% € 100.4k
Wolfgang Laux	Employee Representative Director	3.5yrs	€107.00k	0.00031% € 388.9k

4.5yrs

平均在職期間

61.5yo

平均年齢

経験豊富なボード: 0O59の取締役会は経験豊富であると考えられます ( 4.2年の平均在任期間)。

Sanofi マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Sanofi Announces Board and Committee Appointments

Recent updates

Third quarter 2024 earnings released: EPS: €2.25 (vs €2.02 in 3Q 2023)

Sanofi Reportedly in Talks with French Government over Opella Sale

Clayton, Dubilier & Rice Reportedly Nears €15 Billion Deal for Sanofi Consumer Health Unit

Sanofi Healthcare Bidders Reportedly Revising Offers over Talc Concerns

Sanofi Reportedly Seeks Revised Proposals for Opella

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Sanofi to Report Q2, 2025 Results on Jul 31, 2025

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Sanofi Announces Tolebrutinib Meet Primary Endpoints in HERCULES Phase 3 Study

Investor sentiment improves as stock rises 23%

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: €0.89 (vs €1.15 in 2Q 2023)

Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

Sanofi Ships U.S. Influenza Vaccines for the 2024/25 Season

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Sanofi to Present New Data from its Hemophilia Portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Sarclisa Accepts for FDA Priority Review for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Upcoming dividend of €3.76 per share

Sanofi Announces Board and Committee Appointments

First quarter 2024 earnings released: EPS: €0.91 (vs €1.60 in 1Q 2023)

Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger

Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups

Sanofi Announces Phase 2b Results for Amlitelimab Support Potential for Best-In-Class Maintenance of Response in Atopic Dermatitis

Full year 2023 earnings released: EPS: €4.31 (vs €6.69 in FY 2022)

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34